Personnel Information

写真a

FUJIKI Tamami


Job title

Assistant Professor

Campus Career 【 display / non-display

  • 2014.04
    -
    2015.03
    Tokyo Medical and Dental University, Medical Hospital, Hospital Departments, Department of Internal Medicine, Nephrology, Resident
  • 2017.04
    -
    2021.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Systemic Organ Regulation, Nephrology, Graduate Student
  • 2021.04
    -
    2021.09
    Tokyo Medical and Dental University, Medical Hospital, Hospital Departments, Department of Internal Medicine, Nephrology, Project Assistant Professor
  • 2021.10
    -
    2022.03
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Clinical Medicine, Department of Internal Medicine, Nephrology, Project Assistant Professor
  • 2022.04
    -
    2022.06
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Clinical Medicine, Department of Internal Medicine, Nephrology, Assistant Professor
  • 2022.07
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Systemic Organ Regulation, Nephrology, Assistant Professor

▼display all

 

Published Papers & Misc 【 display / non-display

  1. Hara Y, Ando F, Oikawa D, Ichimura K, Yanagawa H, Sakamaki Y, Nanamatsu A, Fujiki T, Mori S, Suzuki S, Yui N, Mandai S, Susa K, Mori T, Sohara E, Rai T, Takahashi M, Sasaki S, Kagechika H, Tokunaga F, Uchida S. LRBA is essential for urinary concentration and body water homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2022.07; 119 (30): e2202125119. ( PubMed, DOI )

  2. Tamami Fujiki, Fumiaki Ando, Kana Murakami, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Sci Rep. 2019.06; 9 (1): 9245. ( PubMed, DOI )

  3. Fujiki Tamami, Hirasawa Suguru, Watanabe Seishi, Iwamoto Shunsuke, Ando Ryoichi. 極めて重篤なTAFRO症候群に対してステロイドなしのトシリズマブ治療が奏効した1例(Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome) CEN Case Reports. 2017.05; 6 (1): 105-110. ( ichushi )

Conference Activities & Talks 【 display / non-display

  1. Fujiki T, Ando F, Mandai S, Isobe K, Susa K, Mori T, Nomura N, Sohara E, Rai T, Uchida S.. Tolvaptan and Bardoxolone Methyl Synergistically Activate the Nrf2/HO-1 pathway.. ASN Kidney Week 2019 2019.11.08

  2. Tamami Fujiki, Fumiaki Ando, Kiyoshi Isobe, Takayasu Mori, Koichiro Susa, Naohiro Nomura, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida. Tolvaptan activates Nrf2/HO-1 pathway through PERK phosphorylation. The 52nd Annual Meeting of American Society of Nephrology, Kidney Week 2018 2018.10.26 San Diego